Pharmaceutical Stocks Worth Watching - March 22nd

Key Points

• Abbott Laboratories (ABT), AbbVie (ABBV), and Eli Lilly (LLY) were flagged by MarketBeat’s screener as the three pharmaceutical stocks to watch after posting the highest recent dollar trading volume, offering investors exposure to drug-development upside but also regulatory and R&D risks.
• Abbott is a diversified healthcare company operating in established pharmaceuticals, diagnostics, nutrition, and medical devices, and MarketBeat notes its recent pullback may present a potential buying opportunity.
• AbbVie and Eli Lilly are highlighted for deep drug portfolios—AbbVie with blockbusters like Humira, Skyrizi and Rinvoq plus oncology therapies, and Lilly with leading diabetes and obesity drugs including Mounjaro, Trulicity and Zepbound.

Abbott Laboratories, AbbVie, and Eli Lilly and Company are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, and sell prescription drugs and related medical products, giving investors ownership exposure to the pharmaceutical industry. For investors, they offer potential growth from successful drug development and strong product sales but also carry risks from regulatory approvals, patent expirations, and costly R&D. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read Our Latest Research Report on ABT

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read Our Latest Research Report on ABBV

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.